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Abstract 
The purpose of the present work is to underline the importance of obtaining a standardized procedure to ensure 
and evaluate both clinical and research usability of human tissue samples. The study, which was carried out by the 
Biospecimen Science Working Group of the Spanish Biobank Network, is based on a general overview of the cur‑
rent situation about quality assurance in human tissue biospecimens. It was conducted an exhaustive review of the 
analytical techniques used to evaluate the quality of human tissue samples over the past 30 years, as well as their 
reference values if they were published, and classified them according to the biomolecules evaluated: (i) DNA, (ii) RNA, 
and (iii) soluble or/and fixed proteins for immunochemistry. More than 130 publications released between 1989 and 
2019 were analysed, most of them reporting results focused on the analysis of tumour and biopsy samples. A qual‑
ity assessment proposal with an algorithm has been developed for both frozen tissue samples and formalin‑fixed 
paraffin‑embedded (FFPE) samples, according to the expected quality of sample based on the available pre‑analytical 
information and the experience of the participants in the Working Group. The high heterogeneity of human tissue 
samples and the wide number of pre‑analytic factors associated to quality of samples makes it very difficult to harmo‑
nize the quality criteria. However, the proposed method to assess human tissue sample integrity and antigenicity will 
not only help to evaluate whether stored human tissue samples fit for the purpose of biomarker development, but 
will also allow to perform further studies, such as assessing the impact of different pre‑analytical factors on very well 
characterized samples or evaluating the readjustment of tissue sample collection, processing and storing procedures. 
By ensuring the quality of the samples used on research, the reproducibility of scientific results will be guaranteed.
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Background
Human tissue samples obtained from biopsies, surgical 
specimens, organ transplants and autopsies are a great 
resource to find potential targets to aid clinical decisions 
such as diagnosis and treatment of diseases. Over the 
last decades, the use of human biospecimens has heav-
ily increased in biomedical research in order to evaluate 
the outcome, survival, and new therapies for patients, 
and also to test new hypotheses related to the genetic and 
molecular basis of diseases. Besides, the constant tech-
nology advances for biomarker discovery have led to an 
increasing demand of large sets of human biospecimens 
and for new formats for the preservation of biospecimens 
suitable for these technologies, promoting also the crea-
tion of new human biorepositories [1].
Research on disease biomarkers is one of the main 
requirements for the progress of personalized medicine 
and its use for targeted therapies [2–5]. This clinical 
approach, particularly in Oncology, allows a great num-
ber of patients to access more efficient and safer thera-
peutic protocols, which have been selected according 
to molecular findings in tissue samples obtained from 
patients for diagnostic or therapeutic purposes. Indeed, 
many studies report the sustained discovery of different 
clinical biomarkers with potential application to person-
alized medicine [6]. However, most of them cannot be 
applied to clinical practice due to a lack of high sensitivity 
or/and specificity, compromising its reproducibility and 
its successful clinical implementation [7]. In this context, 
the recruitment of subjects, as well as the selection and 
management of tissues, is critical in biomarker research 
[8, 9].
Specifically, it is well known that the handling of 
human biospecimens during their collection, processing 
and storage can alter their characteristics and influence 
their quality, integrity and/or molecular composition 
[10]. These variations are considered as a bias in bio-
marker discovery, hindering the development of new tar-
geted therapies.
As a result, there is a crucial need for the standardiza-
tion of collection, processing and storage procedures to 
improve the quality of biospecimens, in order to enhance 
the reproducibility of biomarker development. Conse-
quently, in recent years, a large number of strategies have 
been described to standardize and improve the qual-
ity control of human samples for their use in biomedi-
cal research, such as the “Standard PREanalytical Code” 
(SPREC) version 2.0, a method developed and agreed by 
the International Society for Biological and Environmen-
tal Repositories Biospecimen Science Working Group, 
which allows controlling the main pre-analytical factors 
that may have an impact on the integrity of the biologi-
cal sample during its collection, processing and storage. 
SPREC assigns to each sample a code of 7 elements based 
on its pre-analytical characterization, helping to stand-
ardize the quality of the set of samples to be used [11].
There are also some guidelines to guarantee collection 
of clinical and pre-analytical data, such as BRISQ (Bio-
specimen Reporting for Improved Study Quality [12]. 
The aim of BRISQ is to ensure the registration of human 
samples data, including the preanalytical factors which 
could influence the integrity, quality or molecular com-
position such as (a) type of pathology, (b) clinical status 
and features of the patient and (c) handling and preserva-
tion conditions (for example: stabilization, shipping and 
storage conditions).
However, despite the efforts made in the last years, the 
scientific community still lacks a standardized approach 
to ensure and evaluate the clinical and research usabil-
ity of human tissue samples. For these reasons, we have 
undertaken to summarize and give a general overview 
of the current situation concerning quality assurance in 
human tissue biospecimens.
Literature review
The Spanish Biobank Network (SBN), formed by 39 
biobanks, provides mainly samples to the scientific com-
munity to support biomedical research, as well as tech-
nical, ethical and legal advice, and other services related 
to human biological samples. One of its most developed 
areas is the Biospecimen Science, where mainly biolo-
gists and pathologists from 13 biobanks of the SBN, 
participate cooperatively in a working group focused on 
innovation in human tissues handling, (i) for improving 
standards on tissue collection, processing and storage, 
and (ii) for setting a global quality assessment method of 
human tissues for biomedical research.
Firstly, the SBN Biospecimen Science working group 
conducted an exhaustive literature review of the ana-
lytical techniques used to evaluate the quality of human 
tissue samples over the past 30 years, as well as their ref-
erence values if they were published, and classified them 
according to the biomolecules evaluated: (i) DNA, (ii) 
RNA, and (iii) soluble or/and fixed proteins for immu-
nochemistry. The group focused on publications where 
colon, breast, kidney, lung, ovary or brain tissues were 
used, since these organs are the main source of samples 
collected by the participating biobanks.
Secondly, based on results of the literature review and 
the expertise of the participating biobanks, a proposal for 
quality assessment of tissues based on the type of preser-
vation method and biomolecule of interest was led. The 
algorithm was purposed to classify the solid tissue sam-
ples according their expected quality, taking into account 
the type of analytical technique required for the research 
project.
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For the design of the algorithm, the Group made 
a prioritization of pre-analytical factors defined by 
SPREC v.2.0 [11] and BRISQ [12] with the highest 
expected impact on the integrity of tissue samples 
according to the literature. So, the Working Group clas-
sified in three categories (optimal or non-effect, mod-
erate or unknown effect and suboptimal quality) the 
expected quality of the nucleic acids integrity and fixed 
proteins for immunochemistry for each factor, both in 
snap-frozen and in formalin fixed-paraffin embedded 
(FFPE) tissue samples.
Identification of techniques for tissue quality 
assessment
More than 130 publications released between 1989 and 
2019 were analysed, most of them reporting results based 
on the analysis of tumour and samples from biopsy pro-
cedures. Tables 1, 2, 3, 4 show a summary of the analyti-
cal techniques used to evaluate tissue quality, according 
to the analysed biomolecule (RNA, DNA, soluble pro-
teins and antigenicity, respectively). They describe (i) the 
measurement method of the biomolecule, (ii) the analyti-
cal technique used, (iii) the parameters of the evaluated 
Table 1 Summary of publications evaluating quality of RNA samples
Measurement method Analytical technique Evaluated parameter Threshold Organ References
Spectrophotometry UV spectroscopy 
(A260/280) NanoDrop
Quantity and purity Around 2 Human trabecular bone [13–18]
> 1.8 excellent Colon, articular cartilage 






Quantity and purity > 2 non contaminated 
RNA
Articular cartilage and 
subchondral bone
[16]
< 2 contaminated RNA
Electrophoresis RIN, RIS, or equivalent Integrity ≥ 7 high‑integrity RNA Colon, kidney, placenta, 
articular cartilage and 
subchondral bone, tra‑
becular bone, pancreas




creatic, stomach, liver, 
colon, brain
[13, 26, 28–33]
5–6 low integrity Pancreas, breast, thyroid, 
stomach, lung, colon
[26, 34, 35]
3–5 partially degraded Breast, thyroid, stomach, 
lung, colon, kidney, 
pancreas
[14, 26, 33–35]
1–3 totally degraded Trabecular bone, breast, 
thyroid, stomach, lung, 
colon, brain, placental
[13, 17, 27, 34, 36]





< 30% too degraded
28S:18S peak ratio Integrity Around 2 Stomach, pancreas, liver, 
colorectal
[29]
Electrophoretic profile Integrity 2 bands 2000 nt (18S), 
4000 nt (28S) → (Non‑
degraded RNA)
Pancreatic tissue [26, 27]
Diffuse banding indica‑
tive of degraded RNA
Pancreatic tissue [26, 27]
RT‑qPCR 3′:5′ ratio Integrity 1–5 perfectly intact 
mRNA
N/A [39]
> 5 suggests degradation
≥ 10 denatured mRNA
Ct values Functionality Increasing Ct values of 
ABL1, FOSB and JUN 
genes suggest RNA 
degradation
Colon [40]
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biomolecule, (iv) the threshold values and (v) the anatomi-
cal organ analysed.
It should be mentioned that the Group found little infor-
mation focused on quality control of soluble proteins 
(Table  3) and antigenicity, including objective threshold 
values and analytical techniques used (Table  4). For this 
reason, the Working Group decided to include the most 
relevant publications regarding pre-analytical factors and 
its consequent effect on them. Consequently, Tables 3 and 
4 include information regarding the pre-analytical fac-
tor under study for each cited reference and, if known, the 
threshold established to determine the effect of the pre-
analytical factor on the sample.
Consensus on an integrated algorithm for quality 
assessment
With the aim of systematizing the classification of human 
tissue samples according to their expected quality, a cat-
egorization proposal has been drawn up in the present 
study, based on SPREC and BRISQ tools as reference. 
Becker et  al. [73] has already eloquently discussed in a 
review paper the importance of these pre-analytical fac-
tors for the meaningful translation of proteomic methods 
and findings to clinical practice. Next, in order to verify 
the functionality of the proposed categories and to estab-
lish reference ranges of analytical values, an algorithm 
was designed for decision-making based on the different 
Table 4 Summary of publications evaluating antigenicity quality
Analytical technique Evaluated parameter Pre-analytical factor Threshold Organ References
Quantitative IF (AQUA score) ER, HER2, Ki‑67, CK Storage time IF signal decreases 10% in 
4–8 years depending on 
the marker
Breast [65]
Increased marker: 95th per‑
centile of slope for n = M is 
higher than 0
CIT Labile and loss of antigenic‑
ity within 1–2 h of CIT
Breast [66]
Decreased marker: 95th per‑
centile of slope for n = M is 
lower than 0
No changes in marker: 95% 
CI for the slope with both 
n = M and n = 10 × M 
Including the zero slope
Trend up/trend down: 
95% CI for the slope with 
n = 10 × M not including it
Cytokeratin, pERK1/2 and 
pHSP‑27 expression
CIT Negative TQI values (as 
indicator of loss of tissue 
quality) for increasing CIT
Breast [67]
IHC Vimentin Fixation – Melanoma [68]
ER and PgR Fixation, slicing, storage of 
slides
Samples for ER and PgR 
testing are fixed in 10% 
NBF for 6 to 72 h. CIT < 1 h. 
Samples should be sliced 
at 5‑mm intervals. Storage 
of slides for more than 
6 weeks before analysis is 
not recommended
Breast [69]
P‑p27 – – – [70]
SNRPA and SnRNP70 H‑score Fixation H‑score < 60 as a cut off for 
positive signal
Breast [71]
MAP2 Fixation, slicing and storage Decrease of MAP2 immuno‑
reactivity in unfixed and in 
delayed‑fixed
Rat brain [72]
Actin, desmin and progester‑
one receptor staining
Storage time Consistent staining over 
18 years
Mesenchyme [63]
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biomolecules with different susceptibility profiles and on 
the type of sample preservation.
A quality assessment proposal for frozen tissue 
samples
Because of the increasing use of human frozen tissue 
specimens as a gold-standard for molecular analysis, a 
testing approach was designed for frozen tissue samples 
based on RNA evaluation (Fig. 1). As a first step, purity 
and concentration assessment of total RNA through 
spectrophotometry is recommended, since it is a quick 
and relatively simple method to evaluate (1) great dete-
riorations according to SPREC variables suffered during 
storage or analysis, or (2) a low cellular content related to 
its anatomical origin.
In case that an adequate concentration of total RNA 
is obtained and it is necessary to evaluate the suitabil-
ity of the sample to perform gene expression studies, it 
would be advisable to evaluate the potential effect of pre-
analytical factors (SPREC and BRISQ) on RNA integ-
rity (Table  5) to decide if further optional analyses are 
required to determine whether a sample is suitable to the 
research purpose.
If predicted RNA quality is optimal according to pre-
analytical factors, it is suggested to perform an integrity 
analysis of the total RNA through its visualization in an 
Fig. 1 Procedures proposed to evaluate molecular integrity in order to classify the suitability of samples for expected applications
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agarose gel and/or the calculation of the 28S:18S ratio 
using the RNA Integrity Number (RIN). According to 
recent publications, three ranges of RIN values have 
been set up as indicators of molecular integrity. A value 
greater than or equal to 7 is considered a non-degraded 
RNA, and therefore, it is assumed to be a high quality 
sample valid to carry out high-performance gene expres-
sion techniques (arrays, miRNA microarrays, RNA-Seq), 
and to be used in in Next Generation Sequencing (NGS) 
of small RNA. In contrast, RIN values between 5 and 7 
are indicative of RNA slight degradation and, finally, val-
ues below 4 indicate a high level of RNA degradation. The 
use of samples with RIN values included in the latter two 
groups is not valid for high-throughput technologies for 
gene expression analysis. However, they may be suitable 
for strategies whose main objective is to detect present or 
absence of a particular marker, such as Endpoint PCR o 
miRNA detection [19–21, 90, 91].
In contrast, if a moderate RNA quality level is esti-
mated according to pre-analytical variables, more eco-
nomic analytical techniques than RIN can be performed 
to evaluate sample quality. A good choice could be study-
ing transcript degradation of a housekeeping genes set by 
RT-qPCR (GAPDH, ACTB, B2M, 18S, ATP5E, TUBB, for 
example) and evaluate the 3′/5′ ratio, as an indirect indi-
cator of degradation and functionality [39, 92]. In most 
cases, RNA degradation is initiated by a gradual shorten-
ing of the poly(A) tail [93], which modifies the propor-
tion of amplicons of the 3′ and 5′ region. This means that 
values close to 1.0 would indicate no degradation, while 
values further from 1.0 would indicate degradation and 
loss of functionality [94]. Samples with optimal quality 
to perform gene expression assays should present a rate 
of approximately 1.0 for most genes studied. Otherwise, 
if samples with a ratio significantly different from 1.0 are 
detected, they should not be considered for high perfor-
mance analysis [92, 95].
Finally, if a sub-optimal quality is predicted (RIN values 
below 5), RIN determination itself is not a reliable meas-
ure of sample usefulness for RT-PCR or other applica-
tions, and accordingly other parameters should be taken 
into account in “fitness for purpose” decisions [96]. On 
those cases, it would be recommendable to perform end-
point PCR analyses, amplifying different fragments of 
several housekeeping genes, such as G6PD, TBP, HPRT, 
ACTB, GAPDH and then determine amplicon sizes by 
Table 5 Expected quality for frozen tissue samples based on RNA quality assessment according to pre-analytical factors 
prioritized following SPREC and BRISQ recommendations
Type 
of codification
Variable Optimal expected quality Moderate expected quality Sub-optimal expected quality




BRISQ Body temperature 4 °C (post‑mortem) [77] RT 18–28 °C (post‑mortem) [77] Unknown
37 °C (alive)
SPREC Type of sample CEN, CLN, FNA, LCM, PLC, TIS HAR, PEN, TCM ZZZ
SPREC Type of collection A06, BCM, BPS, BSL, BTM, FNA, 
PUN, SRG, SSL, STM, VAC
A12 A24, A48, A72 [77]
SWB
SPREC Warm ischemia time A, B, C, D, N E F, X
SPREC Cold ischemia time A, B, C, D [20, 78] E, N F, X [30, 66, 79]
SPREC Fixation/stabilization type OCT, PXT [80, 81] None Others (ACA, ALD, FOR, HST, 
NAA, NBF, XXX, ZZZ) [83]RNL [32, 82]
SNP [24, 80, 81]
ALL
SPREC Fixation/stabilization time D, E (PXT) [84] A, B, C X
F (ALL, RNL) [85] D, E (ALL, RNL) [85]
N F, G (PTX) [84]
G (ALL, RNL) [85]
X (ALL, PXT, RNL)
SPREC Long‑term storage A, J, N Q, S, W [86] B, V, C, D, E, F, G, H, I, K, T, X P [27, 87]
Z
BRISQ Storage duration < 5 years [88, 89] 5–20 years [89] > 20 years
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electrophoresis, loading the PCR product in an agarose 
gel, to start the quality control analysis. For samples 
showing differential size amplicons, it is assumed that 
whole RNA has enough quality for RT-qPCR assays. 
If only small amplicons are visible, it is considered that 
RNA has been degraded and it is only suitable for miR-
NAs analysis. If no amplicons are visible, the RNA quality 
is not enough for any gene expression study.
In summary, the expected quality of a sample and its 
pre-analytical variables should lead us to starting the pro-
cess of quality assessment with a specific analytical tech-
nique or even a combination of them depending on the 
subsequent application (Fig. 1).
A quality assessment proposal for formalin-fixed 
paraffin-embedded samples
For the FFPE samples, according to the expected qual-
ity of the sample based on a first basic immunochemis-
try of CD31 and/or vimentin, a decision tree is proposed 
for the immunohistochemical process to be carried out 
(Fig. 2) in order to evaluate the antigenicity tissue qual-
ity. The antibodies selected for quality assessment were 
proposed based on the following criteria: (1) since they 
are widely used in Diagnostic Pathology routine, they 
could lead to an easier and rapid implementation of the 
quality control strategy and no changes would be nec-
essary in work routines. Moreover, these antibodies are 
Fig. 2 Procedures proposed to evaluate antigenicity tissue quality, in order to classify the suitability of the sample for the expected application
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economically affordable and available from many reagent 
suppliers; (2) these antibodies are included in the Quality 
Assurance Program of the Spanish Society of Pathology 
(in Spanish: Sociedad Española de Anatomía Patológica, 
SEAP). This fact ensures that they are considered as anti-
bodies used for current immunohistochemical diagnosis; 
(3) they hybridize with targets present in most human 
tissues, both healthy and pathological, which allows the 
quality control system to be robust.
Taking into account the above criteria, Ki-67 and 
TTF-1 were selected as nuclear markers, Vimentin and 
Cytokeratin AE1–AE3 as cytoplasmic markers; and 
CD31 and Beta-catenin as membrane markers. The selec-
tion of antibodies of different localizations inside cells 
also could help to understand how cellular location of a 
specific antigen can influence on its antigenicity preser-
vation, which is currently a controversial concept.
So, in order to perform quality control on FFPE tissues 
a process based on two consecutives stages differentiated 
both by the implementation or not of an antigenic recon-
stitution procedure is recommended (Fig.  2). Antigenic 
retrieval allows recovering the antigenicity lost by the 
epitopes during the fixation process with formaldehyde 
preventing antibody recognition. The antigen retrieval 
process is considered as a key process for antigenicity 
preservation. It is advisable to use it in those samples 
where the concentration of the antigen to be identified is 
very low and in samples that have undergone prolonged 
periods of fixation.
We propose to carry out a first staining process with 
Vimentin and CD31 antibodies without antigenic recon-
stitution. Ki-67 is not included in this first step because 
it is well known that it has a low proportion of antigen 
and, therefore, for its proper function an antigen recov-
ery process must be carried out. Those samples present-
ing high signal with Vimentin and CD31 stain, both in 
number of stained cells and in average intensity, would be 
considered as samples with optimal quality for carrying 
out immunohistochemistry (IHC) experiments. On the 
contrary, slides with low or no signal are recommended 
to be considered as samples of unknown quality.
Meanwhile, to evaluate the quality of those samples 
with unknown standards, it is proposed to carry out the 
second phase of the process but with a previous step of 
antigen retrieval. The procedure involves new staining 
processes, identical to the one carried out previously, but 
also including Ki-67 antibody. Those samples presenting 
a high and positive stain should be considered as sam-
ples with moderate quality to use IHC. The loss of signal 
between stage 1 (without antigen retrieval) and stage 2 
(with antigen retrieval) would be related to pre-analytical 
factors affecting stability and sensitivity of epitope bind-
ing and recognition. Samples presenting no signal for the 
antibodies tested would have to be considered as samples 
of sub-optimal quality to perform IHC analysis.
Discussion and conclusions
Human biological samples from the most prevalent 
chronic and rare diseases are nowadays essential for 
advanced biomedical research. In the case of rare dis-
eases, only collaborative approaches make it possible 
to collect a relevant number of samples with high qual-
ity associated clinical data [97, 98], while it is essential 
for any collection that the quality of samples remains 
homogenous. However, the emerging lack of reproduc-
ibility of scientific results is a relevant international 
problem, especially in the development of clinical bio-
markers for the diagnosis, treatment and follow-up of a 
large number of diseases [99]. Regarding tissue samples, 
the availability of analytical techniques to assess their 
quality is important and necessary to ensure reproduc-
ibility of scientific results. Fortunately, the identification 
of pre-analytical factors affecting integrity of samples has 
been very well developed in international initiatives, as 
SPREC, BRISQ, MIABIS, etc. Nevertheless, a standard-
ized and extensive method to determine the usability of 
a sample for a particular analytical technique, or even for 
general tissue samples quality evaluation, has not been 
developed in detail. The availability of these methods, 
as proposed in the present work, would reduce the bias 
posed by a specific group of samples selected for a study. 
In addition, these methods would allow the identification 
of threshold values to determine the impact of each pre-
analytical factor on the quality, integrity and functionality 
of tissue samples, allowing the optimization of handling, 
preservation and storage procedures.
Recent developments in national and international 
regulations on human biospecimens for research present 
biobanks as organizations aimed at supplying biological 
material with the highest quality requirements to sup-
port biomedical research [100]. In Spain, biobanks have 
a specific national legal regulation and normally operate 
under quality management systems and standardized 
operation procedures (SOPs) to guarantee the minimum 
bias among preserved tissue samples. Biobanking staff 
is increasingly aware of the impact that pre-analytical 
factors may have on the handling of tissue samples and, 
moreover, of the importance of having analytical tools 
available for taking fundamental and strategic decisions 
in biobanks.
In 2009, with the aim of promoting the biomedical 
research in Spain, a solid network of biobanks, the SBN 
was created to improve the overall quality of samples for 
research use. At present, 39 biobanks are members of 
the network, including regional networks of biobanks, 
population biobanks, disease-specific biobanks and 
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neurological biobanks, among others. Despite being a 
numerous, complex and heterogeneous network, three 
common objectives have been established: (i) to promote 
the biomedical research by supplying samples with the 
maximum guarantee of quality; (ii) to collaborate in order 
to achieve the best service for the researchers; and (iii) to 
improve the knowledge in Biospecimen Science, in order 
to help on strategic decisions such as the implementation 
of a national quality program in biobanks. The entire net-
work operates under a strategic plan 2018–2020, and the 
executive part is configured by 5 programs focused on (1) 
engagement of researchers and recruitment of collabora-
tive scientific groups, (2) visibility and accessibility of the 
available collections and services, (3) R&D in biobank-
ing, (4) internal and external communication, (5) specific 
training in biobanking procedures and network coordina-
tion. All the activity is supported by an internal structure 
formed by a Coordination Office, a Quality Committee, 
an Advisory Events Committee and an Advisory Ethical-
legal Committee, headed by a coordinator advised by the 
Steering Committee following the recommendations of 
an Advisory External Scientific Committee. Similar initi-
atives on quality issues are faced in Europe, solved in part 
with the establishment of the European Research Infra-
structure for Biobanking and Biomolecular Resources 
(BBMRI-ERIC), formed by national biobank networks, 
dedicated to providing researchers with the support they 
need to find new treatments. In all these networks, a 
particular concern for global quality of samples and the 
implementation of specific quality tests are addressed in 
order to improve the homogenization and standardiza-
tion, and in consequence, the reproducibility of the scien-
tific results worldwide.
To help on that issue, our Working Group has con-
ducted thorough review of the literature and has shared 
common expertise between its members on a wide range 
of preanalytical factors and analytical tests. As a result, 
we have designed, two algorithms for the classification of 
biobank tissue samples according to their expected level 
of performance in various analytical procedures. Both 
algorithms are based on (1) a selection of preanalytical 
data that are relevant for the final quality of samples; and 
(2) on a multi-step evaluation of samples by selected ana-
lytical methods that allow a final classification in terms of 
expected sample quality. One of the algorithms is aimed 
at defining sample quality for frozen tissue samples, while 
a second algorithm is directed to FFPE samples.
However, the great heterogeneity of human tissue sam-
ples and the large number of pre-analytical factors asso-
ciated with the quality of samples makes it very difficult 
to harmonize the quality criteria. Nonetheless, assessing 
the integrity of the tissue itself and derived biomolecules, 
such as its antigenicity, as the method we propose, will 
help to evaluate if stored human tissue samples fit for the 
purpose for which they were collected, as well as if they 
are suitable for other unspecified uses not considered 
previously.
To conclude, the analytical strategies and techniques 
that are presented here constitute a first step to evaluate 
the real impact of pre-analytical factors. The implemen-
tation of such analytical methods will allow the periodi-
cal evaluation of the need to perform readjustments in 
collection, processing and storing processes to ensure the 
availability of well characterized human tissue samples 
for their use in biomedical research.
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